香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或因倚賴該等內容而引致的任 何損失承擔任何責任。 董事會會議召開日期 天安卓健有限公司（「本公司」）董事會（「董事會」）謹此公佈，本公司將於二零二五 年二月二十八日（星期五）舉行董事會會議，藉以（其中包括）批准本公司及其附屬 公司截至二零二四年十二月三十一日止年度之全年業績及其刊發，以及考慮派發股息 （如有）。 承董事會命 天安卓健有限公司 公司秘書 薛寶鈴 香港，二零二五年二月十八日 於本公佈日期，董事會由執行董事江木賢先生、郭美保先生及周海英先生；非執行董事李成輝先生 （主席）、王大鈞先生、高兆元先生及張園園女士；以及獨立非執行董事夏曉寧博士、王永權博士、 楊麗琛女士及曹丹先生組成。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全部或任何部份內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 董事會藉此機會感謝江先生及王先生在任期間為本公司所作出的寶貴貢獻，並歡迎 薛女士履新。 代表董事會 天安卓健有限公司 執行董事 江木賢 香港，二零二五年一月十日 於本公佈日期，董事會由執行董事江木賢先生、郭美保先生及周海英先生；非執行董事李成輝 先生（主席）、王大鈞先生、高兆元先生及張園園女士；以及獨立非執行董事夏曉寧博士、 王永權博士、楊麗琛女士及曹丹先生組成。 更改公司秘書 及 授權代表 天安卓健有限公司（「本公司」）之董事會（「董事會」）謹此宣佈，江木賢先生 （「江先生」）已辭任本公司之公司秘書（「公司秘書」），自二零二五年一月十日 起生效。江先生已確認彼與董事會並無意見分歧，亦無任何事宜就彼之辭任需提請 香港聯合交易所有限公司（「聯交所」）或本公司股東垂注。 董事會欣然宣佈，薛寶鈴女士（「薛女士」）已獲委任為公司秘書及聯交所上市規則 第3.05條項下之本公司授權代表（「授權代表」），以代替現有授 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 天安卓健有限公司 呈交日期： 2024年12月31日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | | 00383 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | 佔有關事件前的現有已發 | | 庫存股份變動 | 每股發行/出售價 ...

Appleby Global Corporate Services (Bermuda) Limited Canon's Court, 22 Victoria Street, PO Box HM 1179, Hamilton HM EX Bermuda 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 (1)更改百慕達主要股份登記及過戶處 及 (2)更改香港股份登記及過戶分處 (1) 更改百慕達主要股份登記及過戶處 天安卓健有限公司（「本公司」）董事會（「董事會」）宣佈，自二零二五年一月一日 起，本公司於百慕達之主要股份登記及過戶處將更改為： 承董事會命 天安卓健有限公司 執行董事 江木賢 香港，二零二四年十二月三十日 於本公佈日期，董事會由執行董事江木賢先生、郭美保先生及周海英先生；非執行董事李成輝 先生（主席）、王大鈞先生 、高兆元先生及張園園女士；及獨立非執行董事夏曉寧博士、 王永權博士、楊麗琛女士及曹丹先生組成。 – 2 – (2) 更改香港股份 ...

獨立非執行董事 夏曉寧博士 王永權博士 楊麗琛女士 曹 丹先生 董事會設立6個委員會。下表提供各董事會成員在該等委員會中所擔任的職位。 董事名單與其角色和職能 天安卓健有限公司董事會（「董事會」）成員載列如下： 執行董事 江木賢先生 郭美保先生 周海英先生 非執行董事 李成輝先生 (主席) 王大鈞先生 高兆元先生 張園園女士 (更新日期： 二零二四年十二月三十日) | 董事 | 董事委員會 | 審核委員會 | 提名委員會 | 薪酬委員會 | 執行委員會 | 投資委員會 | 環境、社會和 管治委員會 | | --- | --- | --- | --- | --- | --- | --- | --- | | 江木賢先生 | | - | C | M | C | M | M | | 郭美保先生 | | - | - | - | M | M | M | | 王大鈞先生 | | - | - | M | - | C | M | | 高兆元先生 | | M | - | M | - | M | - | | 夏曉寧博士 | | M | M | C | - | - | - | | 王永權博士 | | C | M | M | - | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 (1)董事變更 及 (2)董事委員會組成變更 天安卓健有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事（「董事」）會 （「董事會」）欣然宣佈：- (1) 董事變更 (i) 董事辭任 張健先生（「張先生」）已辭任本公司獨立非執行董事（「獨立非執行董事」）及 本公司審核委員會、提名委員會及薪酬委員會各自之成員，自二零二四年十二月三 十日起生效，以投入更多時間於其他事務。 張先生確認彼與董事會概無意見分歧，亦不知悉任何有關彼辭任之事宜而須予提呈 本公司股東（「股東」）及香港聯合交易所有限公司（「聯交所」）垂注。 張先生自二零零六年起擔任本公司董事。董事會藉此機會就張先生於其任期內向本 公司作出之寶貴的指導及貢獻向彼致以誠摯感謝。 曹先生之履歷載列如下： 曹先生，現年四十九歲，持有華東政法大學法學學士學位及復旦大學法律碩 士學位。曹先生現為上海瀚元律師事務所管理合伙人及中國海事仲裁委員會 仲裁員。曹先生 ...

[Company Information](index=4&type=section&id=Company%20Information) The report provides essential corporate governance and operational details, including board composition, committee structures, and key service providers - The report provides basic corporate governance and operational information, including the composition of the company's board of directors, various committees (audit, nomination, remuneration), principal bankers, registered office, company secretary, auditor, and share registrar[7](index=7&type=chunk)[8](index=8&type=chunk) [Financial Statements](index=6&type=section&id=Financial%20Statements) [Condensed Consolidated Statement of Profit or Loss](index=6&type=section&id=Condensed%20Consolidated%20Statement%20of%20Profit%20or%20Loss) For the six months ended June 30, 2024, the Group's total revenue increased by approximately **8%** to **HKD 822 million**, with operating profit surging **85%** to **HKD 61.79 million**, driven by higher gross profit and reduced administrative expenses, leading to a **5-fold increase** in profit for the period to **HKD 29.08 million** and **HKD 21.66 million** attributable to owners of the company Condensed Consolidated Statement of Profit or Loss Summary | Metric | For the six months ended June 30, 2024 (HKD Thousands) | For the six months ended June 30, 2023 (HKD Thousands) | Year-on-year Change | | :--- | :--- | :--- | :--- | | Revenue | 821,529 | 760,951 | +8.0% | | Gross Profit | 183,001 | 149,567 | +22.4% | | Operating Profit | 61,792 | 33,362 | +85.2% | | Finance Costs | (15,707) | (26,520) | -40.8% | | Profit Before Tax | 46,085 | 6,842 | +573.6% | | Profit for the Period | 29,081 | 4,604 | +531.6% | | Profit Attributable to Owners of the Company | 21,659 | 1,310 | +1553.4% | | Basic Earnings Per Share | 1.99 HK cents | 0.17 HK cents | +1070.6% | [Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income](index=8&type=section&id=Condensed%20Consolidated%20Statement%20of%20Profit%20or%20Loss%20and%20Other%20Comprehensive%20Income) The Group reported total comprehensive income of **HKD 29.08 million** for the period, a significant turnaround from a **HKD 16.87 million** loss in the prior year, primarily due to the absence of substantial exchange differences loss this period Total Comprehensive Income Movement | Metric | For the six months ended June 30, 2024 (HKD Thousands) | For the six months ended June 30, 2023 (HKD Thousands) | | :--- | :--- | :--- | | Profit for the Period | 29,081 | 4,604 | | Exchange differences arising from translation of overseas operations | – | (21,478) | | **Total Comprehensive Income for the Period** | **29,081** | **(16,874)** | [Condensed Consolidated Statement of Financial Position](index=9&type=section&id=Condensed%20Consolidated%20Statement%20of%20Financial%20Position) As of June 30, 2024, the Group's total assets were approximately **HKD 3.48 billion**, largely stable compared to year-end 2023, while net assets slightly increased to **HKD 1.89 billion**, and notably, net current assets improved **43%** from **HKD 216 million** to **HKD 309 million**, despite total borrowings rising from **HKD 760 million** to **HKD 804 million** Condensed Consolidated Statement of Financial Position Summary | Metric | June 30, 2024 (HKD Thousands) | December 31, 2023 (HKD Thousands) | Change | | :--- | :--- | :--- | :--- | | **Non-current Assets** | **2,175,673** | **2,175,485** | **~0%** | | **Current Assets** | **1,305,644** | **1,360,768** | **-4.1%** | | **Total Assets** | **3,481,317** | **3,536,253** | **-1.6%** | | **Current Liabilities** | **996,215** | **1,144,872** | **-13.0%** | | **Non-current Liabilities** | **595,236** | **519,736** | **+14.5%** | | **Total Liabilities** | **1,591,451** | **1,664,608** | **-4.4%** | | **Net Assets** | **1,889,866** | **1,871,645** | **+1.0%** | | **Total Equity** | **1,889,866** | **1,871,645** | **+1.0%** | [Condensed Consolidated Statement of Cash Flows](index=13&type=section&id=Condensed%20Consolidated%20Statement%20of%20Cash%20Flows) For the period, the Group's cash and cash equivalents decreased by **HKD 59.55 million**, with net cash outflow from operating activities of **HKD 11.67 million** contrasting with a **HKD 118 million** inflow last year, while investing activities resulted in a **HKD 71.05 million** outflow mainly for property, plant, and equipment additions, and financing activities generated a **HKD 23.18 million** inflow Condensed Consolidated Statement of Cash Flows Summary | Metric | For the six months ended June 30, 2024 (HKD Thousands) | For the six months ended June 30, 2023 (HKD Thousands) | | :--- | :--- | :--- | | Net cash from operating activities | (11,672) | 118,120 | | Net cash used in investing activities | (71,049) | (52,731) | | Net cash from financing activities | 23,176 | 162,633 | | **Net decrease in cash and cash equivalents** | **(59,545)** | **228,022** | | Cash and cash equivalents at beginning of period | 890,266 | 589,050 | | **Cash and cash equivalents at end of period** | **830,721** | **822,019** | [Notes to the Financial Statements](index=15&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Financial%20Statements) [Changes in Accounting Policies](index=16&type=section&id=3.%20Changes%20in%20accounting%20policy%20for%20measurement%20of%20land%20and%20buildings) The Group changed its accounting policy for land and buildings from revaluation to cost model, aligning with its holding company and industry practice, with retrospective application and restatement of 2023 comparative figures impacting various financial metrics including cost of goods and services, operating profit, profit for the period, and earnings per share - The Group changed the measurement method for land and buildings from fair value revaluation model to cost model, with retrospective adjustment for this accounting policy change[23](index=23&type=chunk) - This change resulted in the restatement of 2023 comparative operating profit from **HKD 29.32 million** to **HKD 33.36 million**, and profit for the period from **HKD 0.56 million** to **HKD 4.60 million**[24](index=24&type=chunk) [Revenue Analysis](index=21&type=section&id=4.%20Revenue) The Group's total revenue primarily derives from contracts with customers, with hospital fees and charges being the largest source, accounting for over **97%**, and the healthcare segment contributing the vast majority of revenue, all generated in China 2024 H1 Revenue Composition (HKD Thousands) | Revenue Source | Amount | Percentage | | :--- | :--- | :--- | | Hospital fees and charges | 800,390 | 97.4% | | Elderly care related services and sales of nutritional products | 17,789 | 2.2% | | Rental income | 3,350 | 0.4% | | **Total** | **821,529** | **100%** | Revenue from Contracts with Customers by Business Segment (HKD Thousands) | Business Segment | 2024 H1 | 2023 H1 | | :--- | :--- | :--- | | Healthcare | 800,390 | 733,887 | | Elderly Care | 17,789 | 22,445 | | Property Development | – | 130 | | **Total** | **818,179** | **756,462** | [Segment Information](index=26&type=section&id=5.%20Segment%20Information) The healthcare segment is the Group's core, contributing **HKD 800 million** in revenue and **HKD 82.25 million** in segment profit, while elderly care, property development, and property investment segments all reported losses, with healthcare also accounting for the majority of the Group's assets and liabilities 2024 H1 Segment Performance (HKD Thousands) | Segment | Revenue | Segment Profit/(Loss) | | :--- | :--- | :--- | | Healthcare | 800,390 | 82,250 | | Elderly Care | 18,942 | (25,735) | | Property Development | – | (4,210) | | Property Investment | 2,197 | (16,096) | | Financial Services | – | (13) | | Securities Trading and Investment | – | (363) | [Earnings Per Share](index=34&type=section&id=11.%20Earnings%20Per%20Share) Basic earnings per share for the period significantly increased to **1.99 HK cents** from **0.17 HK cents** (restated) in the prior year, primarily driven by a substantial rise in profit attributable to owners of the company, with no diluted earnings per share presented due to the absence of potential dilutive shares Basic Earnings Per Share Calculation | Metric | 2024 H1 | 2023 H1 (Restated) | | :--- | :--- | :--- | | Profit Attributable to Owners of the Company (HKD Thousands) | 21,659 | 1,310 | | Weighted average number of ordinary shares (Shares) | 1,086,005,457 | 758,959,038 | | **Basic Earnings Per Share** | **1.99 HK cents** | **0.17 HK cents** | [Borrowings](index=40&type=section&id=16.%20Borrowings) As of June 30, 2024, the Group's total borrowings increased to **HKD 804 million** from **HKD 760 million** at year-end 2023, with a notable rise in unsecured term loans, and approximately **35%** of borrowings maturing within one year and **54%** over two years Borrowings Composition and Repayment Schedule (HKD Thousands) | Type of Borrowing | June 30, 2024 | December 31, 2023 | | :--- | :--- | :--- | | Secured bank borrowings | 62,516 | 82,930 | | Unsecured bank borrowings | 366,923 | 355,692 | | Unsecured term loans | 374,725 | 321,428 | | **Total Borrowings** | **804,164** | **760,050** | | **Repayment Period** | | | | Within one year | 278,046 | 312,561 | | Over one year but within two years | 94,563 | 122,587 | | Over two years but within five years | 431,555 | 324,902 | [Litigation](index=50&type=section&id=23.%20Litigation) The Group's indirect wholly-owned subsidiary, Tongren Medical Industry Group Co., Ltd., received a writ of summons in July 2024 concerning a claim of approximately **RMB 143 million**, which the company, based on Chinese legal advice, believes to be without legal merit and not expected to materially impact the Group's operations or financial position - Subsidiary Tongren Medical faces a claim lawsuit of approximately **RMB 143 million**[84](index=84&type=chunk) - Company management, based on legal advice, believes the lawsuit will have no material impact on the Group's operations or financial position[84](index=84&type=chunk) [Auditor's Review Report](index=51&type=section&id=Review%20Report%20on%20Condensed%20Consolidated%20Interim%20Financial%20Statements) The auditor, BDO Limited, has reviewed the interim condensed consolidated financial statements and issued a standard unqualified review conclusion - BDO Limited, the auditor, has reviewed the interim condensed consolidated financial statements[85](index=85&type=chunk) - The review concluded that the auditor found no matters indicating the interim financial information was not prepared, in all material respects, in accordance with Hong Kong Accounting Standard 34 "Interim Financial Reporting," representing a standard unqualified review conclusion[88](index=88&type=chunk) [Management Discussion and Analysis](index=53&type=section&id=Management%20Discussion%20and%20Analysis) [Financial Performance Review](index=53&type=section&id=Financial%20Performance) In H1 2024, the Group's total revenue grew **7.47%** to **HKD 822 million**, with profit attributable to owners surging **15.5 times** to **HKD 21.66 million**, primarily driven by increased healthcare segment revenue, lower medical consumables and finance costs, partially offset by higher pharmaceutical costs and fair value losses on investment properties, resulting in basic earnings per share of **1.99 HK cents** - Profit attributable to owners increased **15.5 times** year-on-year, primarily driven by: - Increased operating revenue in the healthcare segment following the relaxation of COVID-19 controls in China - Reduced medical consumables costs - Increased bank deposit interest income - Decreased finance costs for borrowings in China[89](index=89&type=chunk) Key Financial Indicators | Metric | 2024 H1 | 2023 H1 (Restated) | | :--- | :--- | :--- | | Total Revenue | HKD 822 million | HKD 764 million | | Profit Attributable to Owners | HKD 21.66 million | HKD 1.31 million | | Basic Earnings Per Share | 1.99 HK cents | 0.17 HK cents | [Business Review](index=53&type=section&id=Business%20Review) The Group primarily engages in healthcare, elderly care, property investment and development, securities investment, and financial services, with the healthcare segment showing strong performance as the main growth engine, while the elderly care segment faced intensified competition, and property and investment-related businesses performed weakly [Healthcare Segment](index=54&type=section&id=Healthcare%20Segment) The healthcare segment's revenue grew to **HKD 800 million** and profit rose to **HKD 82.25 million**, with Nanjing and Kunming hospitals making progress in research, specialty development, and market expansion despite DRGs payment reform challenges, and Kunming Hospital Phase II main construction completed, laying a foundation for future growth Healthcare Segment Financial Performance (HKD Thousands) | Metric | 2024 H1 | 2023 H1 (Restated) | | :--- | :--- | :--- | | Revenue | 800,390 | 733,887 | | Profit | 82,250 | 34,638 | | EBITDA | 137,731 | 95,033 | - The main construction of Kunming Hospital Phase II (including the comprehensive inpatient building, oncology and nuclear medicine building, and rehabilitation medicine building) has been completed, and preparations for interior decoration tendering have begun[97](index=97&type=chunk) [Elderly Care Segment](index=60&type=section&id=Elderly%20Care%20Segment) The elderly care segment's revenue fell to **HKD 18.94 million** and loss expanded to **HKD 25.74 million**, primarily due to property sales no longer being a main driver and increased competition leading to member attrition in community operations, with the segment now focusing on stable operations and efficiency improvement Elderly Care Segment Financial Performance (HKD Thousands) | Metric | 2024 H1 | 2023 H1 (Restated) | | :--- | :--- | :--- | | Revenue | 18,942 | 22,952 | | Loss | (25,735) | (17,969) | [Property Development and Investment](index=62&type=section&id=Property%20Development%20and%20Investment) The property development segment reported no revenue and a **HKD 4.21 million** loss for the period, while the property investment segment had **HKD 2.20 million** in rental income but a **HKD 9.13 million** fair value loss on investment properties, resulting in a **HKD 6.10 million** loss Property-Related Segment Financial Performance (HKD Thousands) | Segment | Revenue | Profit/(Loss) | | :--- | :--- | :--- | | Property Development | – | (4,210) | | Property Investment | 2,197 | (6,096) | [Securities Trading and Investment](index=62&type=section&id=Securities%20Trading%20and%20Investment) The securities trading and investment business generated no revenue and incurred a **HKD 0.363 million** loss for the period, primarily from fair value losses on investments held for trading, with the portfolio's carrying value at period-end being **HKD 6.30 million**, mainly invested in Hong Kong-listed companies in the property and construction sectors Investments Held for Trading Portfolio (HKD Thousands) | Item | June 30, 2024 Carrying Value | | :--- | :--- | | **By Region** | | | Hong Kong | 4,579 | | Australia | 1,278 | | Philippines | 441 | | **By Industry** | | | Property and Construction | 5,304 | | Other | 994 | | **Total** | **6,298** | [Financial Resources and Risk Management](index=66&type=section&id=Financial%20Resources%2C%20Borrowings%2C%20Capital%20Structure%20and%20Exchange%20Rate%20Fluctuation%20Risks) As of June 30, 2024, the Group's gearing ratio (net borrowings/total equity) was approximately **-2.4%**, indicating a net cash position and sound financial health, with total borrowings of **HKD 804 million**, and the Group will closely monitor foreign exchange risk as assets, liabilities, and transactions are primarily denominated in HKD and RMB Financial Position Summary | Metric | June 30, 2024 | December 31, 2023 | | :--- | :--- | :--- | | Total Borrowings | HKD 804 million | HKD 760 million | | Gearing Ratio | -2.4% | -8.7% | | Total Assets Pledged | HKD 626 million | HKD 670 million | - Net proceeds of approximately **HKD 309 million** from the rights issue in June 2023, earmarked for Kunming Hospital Phase II development, remained unutilized as of the reporting period end[114](index=114&type=chunk) [Outlook](index=69&type=section&id=Outlook) Facing a challenging macro environment, the Group will adopt a cautious approach, focusing on "cost control, energy saving, development, and efficiency enhancement," with the healthcare segment promoting specialized disciplines for new growth drivers, the elderly care segment exploring integrated medical-elderly care models and smart health platforms, and the Group continuously reviewing and adjusting business and investment strategies to create shareholder value - **Healthcare Segment Outlook:** - Strengthen process control and enhance operational efficiency to cope with external impacts - Introduce experts to develop specialized disciplines and disease centers (e.g., endoscopy centers, oncology departments) - Develop high-end medical services to create new business growth engines[122](index=122&type=chunk)[123](index=123&type=chunk) - **Elderly Care Segment Outlook:** - Build a smart health and elderly care big data platform and medical-elderly care supply chain - Explore integrated medical-elderly care business models and engage in businesses like senior universities to cultivate potential clients - Enhance marketing and operational efficiency of nursing hospitals, focusing on dementia care specialties[124](index=124&type=chunk)[125](index=125&type=chunk) - **Overall Strategy:** - The Group plans to adopt a cautious approach in a challenging business environment - Closely review and adjust business and investment strategies to adapt to the economic landscape and create higher value for shareholders[126](index=126&type=chunk) [Directors' and Shareholders' Interests](index=72&type=section&id=Directors%27%20and%20Shareholders%27%20Interests) [Directors' and Major Shareholders' Interests](index=72&type=section&id=Directors%27%20Interests) The report details the shareholdings of directors and major shareholders, with Mr. Li Cheng Hui deemed to hold **51.20%** of the company's shares through his interest in the ultimate holding company, United Asia Finance Limited, and other major shareholders including Tsinghua Tongfang Co., Ltd. (**18.42%**), China Minsheng Investment Corp., Ltd. (**9.21%**), and Ms. Chong Shun Yee (**8.98%**) Major Shareholders' Shareholding (as of June 30, 2024) | Shareholder Name | Capacity/Relationship | Number of Shares Held | Approximate Percentage of Shareholding | | :--- | :--- | :--- | :--- | | Mr. Li Cheng Hui | Held by controlled corporations (through United Asia Finance and Tian An) | 556,097,010 | 51.20% | | Tsinghua Tongfang Co., Ltd. | Held by controlled corporations | 200,000,000 | 18.42% | | China Minsheng Investment Corp., Ltd. | Held by controlled corporations | 100,000,000 | 9.21% | | Ms. Chong Shun Yee | Held by controlled corporations | 97,514,540 | 8.98% | [Corporate Governance and Other Information](index=77&type=section&id=Corporate%20Governance%20and%20Other%20Information) The company complied with the Listing Rules' Corporate Governance Code during the reporting period, with the audit committee reviewing the interim report and no share buybacks, sales, or redemptions occurring - The company complied with the Corporate Governance Code in the Listing Rules during the reporting period[136](index=136&type=chunk) - The Audit Committee has reviewed this interim report and the unaudited condensed consolidated interim financial statements[139](index=139&type=chunk) - During the reporting period, neither the company nor any of its subsidiaries repurchased, sold, or redeemed any of the company's shares[140](index=140&type=chunk)

[Clarification Announcement](index=1&type=section&id=%E6%BE%84%E6%B8%85%E5%85%AC%E4%BD%88) This announcement corrects a clerical error in segment asset data from the previously published interim results [Purpose and Background of the Announcement](index=1&type=section&id=%E5%85%AC%E5%91%8A%E7%9B%AE%E7%9A%84%E4%B8%8E%E8%83%8C%E6%99%AF) This announcement corrects a clerical error regarding segment asset data in the interim results for the six months ended June 30, 2024 - This announcement serves to clarify the unaudited interim results announcement published on August 2, 2024[1](index=1&type=chunk) - The company identified an inadvertent clerical error in the "Segment assets and liabilities" section, resulting in **incorrect segment asset data**[1](index=1&type=chunk) [Details of Financial Data Correction](index=1&type=section&id=%E8%B4%A2%E5%8A%A1%E6%95%B0%E6%8D%AE%E6%9B%B4%E6%AD%A3%E8%AF%A6%E6%83%85) The correction reallocates asset values between the Healthcare and Elderly care segments for two reporting periods, with no change to total group assets Comparison of Segment Asset Data Before and After Correction | Segment | Reporting Date | Before Correction (HK$) | After Correction (HK$) | | :--- | :--- | :--- | :--- | | **Healthcare segment** | **June 30, 2024** | 1,701,044,000 | **1,822,738,000** | | **Elderly care segment** | **June 30, 2024** | 797,197,000 | **675,503,000** | | **Healthcare segment** | **December 31, 2023** | 1,762,872,000 | **1,865,838,000** | | **Elderly care segment** | **December 31, 2023** | 790,948,000 | **687,982,000** | [Other Information](index=1&type=section&id=%E5%85%B6%E4%BB%96%E4%BF%A1%E6%81%AF) All other information in the original interim announcement remains unchanged, and the current Board of Directors is listed - Except for the aforementioned corrections, all other information in the original interim results announcement remains unchanged[1](index=1&type=chunk) - The announcement lists the Board of Directors as of the announcement date, comprising executive, non-executive, and independent non-executive directors[2](index=2&type=chunk)

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全部或任何部份內容而產生或 因倚賴該等內容而引致之任何損失承擔任何責任。 MEDICARE （於百慕達註冊成立之有限公司） （股份代號：383） 截至二零二四年六月三十日止六個月 之未經審核中期業績 天安卓健有限公司（「本公司」）之董事會（分別為「董事」及「董事會」）謹此宣佈， 本公司及其附屬公司（「本集團」）截至二零二四年六月三十日止六個月之未經 審核綜合業績連同二零二三年度同期之比較數字如下： 簡明綜合損益表 截至二零二四年六月三十日止六個月 | --- | --- | --- | --- | |----------------------------------------|-------|-------------------------------------------------------------|-------------------------------------------| | | 附註 | 截至六月三十日止六個月 \n二零二四年 千港元 （未 ...

Financial Performance - The total revenue for the year ended December 31, 2023, was HKD 1,572,305,000, representing an increase of approximately 9.35% compared to HKD 1,437,863,000 for the year ended December 31, 2022[9]. - The company reported a profit attributable to owners of HKD 11,295,000, a significant recovery from a loss of HKD 123,574,000 in the previous year[9]. - The basic earnings per share for the year was HKD 0.0122, compared to a basic loss per share of HKD 0.1694 in the previous year[9]. - The healthcare segment recorded revenue growth to HKD 1,521,859,000, up from HKD 1,382,134,000 in the previous year, with profit rising to HKD 85,839,000 from HKD 12,828,000[15]. - The EBITDA for the healthcare segment was HKD 202,095,000, compared to HKD 143,774,000 in the previous year[15]. - The revenue of the elderly care segment decreased to HKD 41,716,000 for the year ended December 31, 2023, down from HKD 49,787,000 in 2022, with a loss of HKD 46,684,000 compared to HKD 51,169,000 in the previous year[28]. - The property development segment's revenue fell to HKD 125,000 in 2023 from HKD 732,000 in 2022, with a loss reduced to HKD 2,065,000 from HKD 24,329,000[33]. - Rental income from investment properties was HKD 5,124,000 in 2023, slightly down from HKD 5,188,000 in 2022, with a profit of HKD 4,481,000 compared to a loss of HKD 9,397,000 in the previous year[34]. - The securities trading and investment segment recorded revenue of HKD 3,481,000 in 2023, down from HKD 22,000 in 2022, with a loss of HKD 2,009,000 compared to HKD 2,594,000 in the previous year[36]. Dividends and Shareholder Value - The company proposed a final dividend of HKD 0.01 per share, totaling approximately HKD 10,860,055, compared to no dividend in the previous year[11]. - The net asset value per share attributable to shareholders was HKD 1.72, down from HKD 2.15 in the previous year[10]. - The company proposed a share consolidation, merging every 20 existing shares into 1 new share with a par value of HKD 0.01, effective February 24, 2023[50]. - The company raised approximately HKD 318.6 million through a rights issue, issuing 362,001,819 shares at a subscription price of HKD 0.88 per share, with net proceeds of about HKD 309.3 million after expenses[52]. Healthcare Services Expansion - The company plans to continue expanding its healthcare services in response to the recovering demand post-pandemic[15]. - The company is focused on enhancing its investment and management capabilities in the healthcare sector, including potential new technologies and market expansion strategies[14]. - Nanjing Hospital established an allergy disease specialty clinic, improving its comprehensive treatment services[19]. - Nanjing Hospital completed the online payment system for medical insurance, significantly reducing patient wait times[19]. - Kunming Hospital plans to expand its key departments, including pathology and oncology, with a physical space adjustment of no less than 300 square meters and the recruitment of 5 staff members for pathology[70]. - The outpatient department will develop specialized services in ophthalmology, ENT, and dental care, focusing on high-value customer segments and personalized care[76]. - The group aims to strengthen its existing comprehensive medical services and traditional specialty areas such as ENT, ophthalmology, cardiology, and gynecology while diversifying into the health sector to enhance its competitive advantage[79]. Operational Efficiency and Cost Control - The company has implemented cost control measures, including optimizing the structure and pricing of medical supplies to reduce costs[30]. - The group will continue to maintain a cautious approach, focusing on improving operational efficiency, controlling costs, and strengthening its medical and technical teams amid a challenging economic environment[82]. - The group aims to create a high-quality, high-margin service system to effectively supplement basic medical services through the development of commercial insurance business and high-end customer membership operations[80]. Staffing and Human Resources - The company employed 2,599 staff as of December 31, 2023, an increase from 2,577 in the previous year[61]. - The elderly care business faced operational challenges, with a 30% average reduction in staff post-pandemic, leading to intensified competition[30]. - The nursing division plans to strengthen marketing efforts and establish referral partnerships with local hospitals and nursing homes to increase occupancy rates[78]. Governance and Corporate Structure - The board consists of ten members, including three executive directors, three non-executive directors, and four independent non-executive directors[161]. - The company has established six committees, including the Executive Committee and the Investment Committee, to assist in governance and oversight[179]. - The company has adopted a compensation policy for employees based on merit, qualifications, and capabilities, with the remuneration committee determining the pay for directors and senior management[146]. - The company has complied with the corporate governance code as per the Hong Kong Stock Exchange rules, ensuring high standards of corporate governance[158]. - The company has established a whistleblower policy to allow employees and stakeholders to report concerns anonymously regarding potential misconduct[199]. Shareholder Information - As of December 31, 2023, Mr. Li Chenghui holds 556,022,010 shares, representing 51.19% of the total issued shares of the company[129]. - The major shareholders include Mr. Li Chenghui, Ms. Li Shuhui, and Mr. Li Chenghuang, each holding 556,022,010 shares, equating to 51.19%[138]. - The company has a total of 1,086,005,457 shares issued as of December 31, 2023, with major shareholders holding approximately 8.98% each[140]. Future Outlook and Strategic Initiatives - The group is advancing the second phase of the Kunming Hospital project, focusing on the development of oncology and nuclear medicine disciplines as a strategic initiative[82]. - The group intends to establish an international department within hospitals to collaborate on high-end medical services, enhancing its service offerings[80]. - The group will review and adjust its business and investment policies to adapt to the challenging economic and investment environment in China, Hong Kong, and the Asia-Pacific region[82].